Going back to the pandemic, a spotlight was put on just how fragile some companies’ supply chains were. Those managing extended sourcing strategies that wrapped around the globe struggled to receive critical components and had manufacturing slowed or even halted. Meanwhile, organizations that maintained close relationships with more localized supply partners faced much fewer challenges.

In recent years, there have been a number of concerns that have further highlighted the fears from long supply chains. Due to everything from logistics issues to natural disasters, medical device manufacturers are taking a long, hard look at their suppliers, where they produce components, the total cost, and the related benefits.

To add the perspective of a U.S.-based manufacturer to the discussion, John Faulkner, President of BMP Medical, responded to several questions in the following Q&A. In this interview, he speaks to why U.S. manufacturing may be an attractive alternative to companies, the drivers of the decision, and what some of the most important factors to consider are.

Sean Fenske: What’s driving interest among medical device manufacturers to reshore to the U.S.?

John Faulkner: I think the number one thing that drives companies to reshore back to the U.S. is a complicated equation comprised of many different variables. However, one of the primary factors included in this decision is…